| Stage | SGRY | % of rev | HCA | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $849M | 100.00% | $19.8B | 100.00% | HCA ×23.38 |
| Gross profit | $596M | 70.18% | $11.3B | 56.77% | SGRY +13.4pp |
| Operating income | $102M | 12.03% | $3.0B | 14.90% | HCA +2.9pp |
| Pre-tax income | $32M | 3.80% | $2.4B | 11.94% | HCA +8.1pp |
| Net income | $30M | 3.50% | $1.8B | 9.32% | HCA +5.8pp |
| Stage | SGRY | HCA | Gap · A − B |
|---|---|---|---|
| Revenue | $849M100.00% | $19.8B100.00% | HCA ×23.38 |
| Gross profit | 70.18%$596M | 56.77%$11.3B | SGRY +13.4pp |
| Operating income | 12.03%$102M | 14.90%$3.0B | HCA +2.9pp |
| Pre-tax income | 3.80%$32M | 11.94%$2.4B | HCA +8.1pp |
| Net income |
| 3.50%$30M |
| 9.32%$1.8B |
| HCA +5.8pp |
No shared counterparties.